Introduction {#section1-1470320316689338}
============

During the past three decades research has progressively shown a new and fascinating world behind the century-old history of the pressoric renin--angiotensin system (RAS), discovered in several seminal steps between 1898^[@bibr1-1470320316689338]^ and 1941.^[@bibr2-1470320316689338][@bibr3-1470320316689338][@bibr4-1470320316689338][@bibr5-1470320316689338][@bibr5-1470320316689338]--[@bibr7-1470320316689338]^ The new world is that of shorter peptides originating from both the decapeptide angiotensin I (Ang I) and the octapeptide angiotensin II (Ang II),^[@bibr8-1470320316689338]^ with Ang-(1−7) being the best known in terms of physiological effects and intracellular signaling pathways (reviewed in Alenina and Santos).^[@bibr9-1470320316689338]^ Interestingly, this early representative of the Ang I/Ang II-derived peptides soon emerged as a potent counterbalance to the vasoconstrictive actions of RAS.

In parallel with the discovery of the structure and actions of the shorter Ang I/Ang II-derived peptides, the simple and earlier view of RAS as a classic endocrine system shifted to a dual concept involving the coexistence of the systemic RAS -- mainly regarding cardiovascular actions -- with the so-called organ-based RAS.^[@bibr10-1470320316689338]^ In this system described in heart,^[@bibr11-1470320316689338]^ kidney,^[@bibr12-1470320316689338]^ brain^[@bibr13-1470320316689338]^ and liver,^[@bibr14-1470320316689338]^ among other organs, the main event is the local formation of Ang II.^[@bibr15-1470320316689338]^ Interestingly, crosstalk between different local RAS systems has physiological and pathological relevance for heart and kidney.^[@bibr16-1470320316689338]^ Even though the 'organ uptake theory' dominated this new view of RAS because it could explain the significant amounts of Ang II found in several organs/tissues,^[@bibr17-1470320316689338]^ the concept was soon expanded to include genes involved in the synthesis of renin,^[@bibr18-1470320316689338],[@bibr19-1470320316689338]^ precursors such as angiotensinogen^[@bibr11-1470320316689338],[@bibr20-1470320316689338]^ and enzymes (from renin to the angiotensin II-converting enzymes, ACE and ACE2).^[@bibr8-1470320316689338],[@bibr21-1470320316689338],[@bibr22-1470320316689338]^ These components were encountered in many different organs, together with local Ang II concentrations significantly higher than those of the circulating peptide.^[@bibr23-1470320316689338]^

Angiotensin-(3−4) {#section2-1470320316689338}
=================

Moving on beyond Ang-(1--7) to the myriad of very short Ang I/Ang II-derived peptides, their formation and their potential functional role were first described in animal and plant tissues and their effects were demonstrated using extracts of these tissues.^[@bibr24-1470320316689338],[@bibr25-1470320316689338]^ One of the shorter peptides that was soon identified for its important physiological relevance was the dipeptide angiotensin-(3--4) (Ang-(3--4) or Val-Tyr). Ang-(3−4) was first purified from rice extracts (sake)^[@bibr25-1470320316689338]^ and promptly assayed for cardiovascular actions.^[@bibr26-1470320316689338],[@bibr27-1470320316689338]^ Earlier work on isolated luminal proximal tubule membranes and Ang II provided evidence that Ang-(3−4) was a metabolite of local renal RAS.^[@bibr8-1470320316689338]^ In plasma, Ang-(3−4) can be formed from angiotensin III (Ang III),^[@bibr27-1470320316689338]^ thus making it a component of both the local and systemic RAS.

A few reports indicated that Ang-(3−4) had significant physiological effects in cardiovascular homeostasis. As well as its clear inhibitory effect of ACE *in vitro*,^[@bibr27-1470320316689338]^ Ang-(3--4) was antiproliferative in cultured smooth muscle cells^[@bibr28-1470320316689338]^ ([Figure 1](#fig1-1470320316689338){ref-type="fig"}), and had vasodilatory effects on the aorta in hypertensive and non-hypertensive rats.^[@bibr29-1470320316689338],[@bibr30-1470320316689338]^ These vascular antagonistic actions with Ang II could also be helped by its free radical reducing and scavenging ability,^[@bibr30-1470320316689338]^ which can be related to the very hydrophobic nature of its molecular moiety.^[@bibr31-1470320316689338]^ Interestingly, Ang-(3−4) is effective when administered orally,^[@bibr26-1470320316689338],[@bibr32-1470320316689338],[@bibr33-1470320316689338]^ a property associated with its resistance to hydrolysis and its high capacity to permeate intestinal cells.^[@bibr34-1470320316689338]^ One mechanism proposed to explain these effects involves [l]{.smallcaps}-type Ca^2+^ channels, independently of Ang II receptors.^[@bibr28-1470320316689338]^ In phase 1 clinical trials, Ang-(3--4) purified from sardine extracts administered orally depressed Ang II and aldosterone plasma levels ([Figure 2(a)](#fig2-1470320316689338){ref-type="fig"}) and had clear antihypertensive effects in mildly hypertensive adults ([Figure 2(b)](#fig2-1470320316689338){ref-type="fig"}).^[@bibr32-1470320316689338]^ Increased Ang I plasma levels indicated that the inhibition of ACE *in vivo* also occurred.^[@bibr32-1470320316689338]^ Interestingly, the plasma levels of Ang-(3--4) are markedly lower in hypertensive than in healthy individuals, levels negatively correlated with systolic pressure.^[@bibr35-1470320316689338]^

![Proliferation of angiotensin II (Ang II)-stimulated vascular smooth muscle cells is inhibited by angiotensin-(3−4) (Ang-(3--4)) (represented by VY) in a dose-dependent manner. This figure shows WST-8 reduction by nicotinamide adenine dinucleotide (NADH) in the presence of 1 μmol/L Ang II and increasing concentrations of Ang-(3--4). The inset shows that antiproliferative action of Ang-(3--4) has a 50% inhibitory concentration (IC~50~) in the micromolar range. Reproduced from Matsui et al.,^[@bibr28-1470320316689338]^ with permission.](10.1177_1470320316689338-fig1){#fig1-1470320316689338}

![Oral treatment of mild hypertensive individuals with 3 mg angiotensin-(3−4) (Ang-(3--4)) (represented by VY), twice daily. (a) Plasma concentration of Ang-(3--4), angiotensin II (Ang II) and aldosterone before and after a 4-week experimental period. Increased levels of circulating Ang-(3--4) are seen in parallel with reduced plasma Ang II and aldosterone, supporting the idea that the dipeptide acts as a systemic angiotensin-converting enzyme inhibitor. (b) Systolic and diastolic blood pressure of hypertensive individuals were reduced during treatment with Ang-(3--4), which persisted for up to 7 weeks after the treatment was interrupted. Modified from Kawasaki et al.,^[@bibr32-1470320316689338]^ with permission.](10.1177_1470320316689338-fig2){#fig2-1470320316689338}

Basal renal levels of Ang-(3--4) are higher than in other tissues and plasma, and renal accumulation was also observed after a single oral administration ([Figure 3](#fig3-1470320316689338){ref-type="fig"}).^[@bibr36-1470320316689338]^ This raises the question as to whether this renal accumulation of Ang-(3--4) was the result of uptake from the circulating plasma or arose from local synthesis, thus being a component of the renal local RAS? From combined use of fluorescent substrates for proteolytic enzymes, specific inhibitors, high performance chromatographic analyses and a family of synthetic peptides derived from Ang I and Ang II, it was found that successive conversion, i.e. of Ang II → Ang-(1--7) → Ang-(1--5) → Ang-(1--4) → Ang-(3--4), is the main route for the formation of Ang-(3--4) in basolateral membranes of proximal kidney tubule cells ([Figure 4](#fig4-1470320316689338){ref-type="fig"}).^[@bibr21-1470320316689338]^ This compartmentalisation of synthesis in basolateral membranes was indicative of a role in the important and varied transport processes − some mediated by ATPases − that carry ions across these membranes towards the renal interstitium. These processes are mostly linked to the homeostasis of body fluid compartments and the regulation of arterial blood pressure.^[@bibr37-1470320316689338],[@bibr38-1470320316689338]^

![Plasma and kidney levels of angiotensin-(3−4) (Ang-(3--4)) after a single oral dose (10 mg/kg) in 18-week old spontaneously hypertensive rats. Although circulating concentrations of the dipeptide return to base levels 6 hours after administration, its level remains higher in the kidney, indicating the existence of a mechanism of tissue concentration or local production of Ang-(3--4). Modified from Matsui et al.,^[@bibr36-1470320316689338]^ with permission.](10.1177_1470320316689338-fig3){#fig3-1470320316689338}

![Enzymes and pathways responsible for angiotensin-(3−4) (Ang-(3--4)) formation in basolateral membranes from sheep kidney proximal tubule cells. Aminopeptidases and neprilysin are key enzymes required for at least one step of each pathway. AP: aminopeptidase; NEP: neprilysin; EP: endopeptidase; APA: aminopeptidase A; PsCP: Plummer's sensitive carboxypeptidase; PCP: prolylcarboxypeptidase; ACE: angiotensin-converting enzyme; APN: aminopeptidase N; DPP: dipeptidylpeptidase. Reproduced from Axelband et al.,^[@bibr21-1470320316689338]^ with permission.](10.1177_1470320316689338-fig4){#fig4-1470320316689338}

Ang-(3−4) and Ca^2+^ and Na^+^ transporters in kidney: interaction with Ang II receptors? {#section3-1470320316689338}
=========================================================================================

Plasma membrane Ca^2+^-ATPase (PMCA) is considered to be the primary active transporter responsible for fine-tuning of Ca^2+^ extrusion from the cytosol.^[@bibr39-1470320316689338]^ In kidney proximal tubule cells, Ca^2+^ stimulates the Ang II-regulated reabsorption of fluid^[@bibr38-1470320316689338]^ and, therefore, small fluctuations of the cation within the cells are significant in homeostasis in body fluid compartments. Ang-(3--4), with a very high affinity, is a potent counteracting agent (A~1/2~ in the femtomolar range) inhibiting PMCA exerted by Ang II in physiological concentrations in tissues ([Figure 5(a)](#fig5-1470320316689338){ref-type="fig"}).^[@bibr40-1470320316689338]^ Mechanistically, Ang-(3--4) acts through a signaling pathway that starts with Ang II-type 2 receptors (AT~2~R) and includes regulatory phosphorylation mediated by cAMP-activated protein kinase (PKA), which is upregulated by Ang-(3--4)-induced dissociation of AT~1~R/AT~2~R heterodimers.^[@bibr40-1470320316689338],[@bibr41-1470320316689338]^ Using a transfected renal cell line overexpressing AT~2~R, Ang-(3--4) acts as an 'allosteric enhancer' and generates very high-affinity Ang II binding sites in this family of receptors ([Figure 5(b)](#fig5-1470320316689338){ref-type="fig"}).^[@bibr41-1470320316689338]^ This seems to be the first step by which Ang-(3--4) switches on an AT~2~R-mediated signaling pathway that counteracts the inhibition of PMCA through the AT~1~R-mediated pathway.

![(a) Angiotensin-(3−4) (Ang-(3--4)) reactivates, with a very high affinity (pA~1/2~ \~15.5), the angiotensin II (Ang II)-inhibited basolateral plasma membrane Ca^2+^-ATPase. Ca^2+^ pump activity was assayed with 10^-10^ mol/L Ang II and increasing concentrations of Ang-(3--4). Modified from Axelband et al.,^[@bibr40-1470320316689338]^ with permission. (b) Ang-(3−4) creates a probable high afﬁnity site for Ang II at Ang II-type 2 receptors at \~10^-12^ mol/L, i.e. with an affinity \~5 orders of magnitude higher than in the absence of Ang-(3−4) (10^-7^ mol/L). The competition binding assay was carried out in HEK 293T cells overexpressing AT~2~R in 10^-10^ mol/L Ang-(3--4). Modified from Axelband et al.,^[@bibr41-1470320316689338]^ with permission.](10.1177_1470320316689338-fig5){#fig5-1470320316689338}

The antihypertensive effects of Ang-(3--4) in spontaneously hypertensive rats (SHRs)^[@bibr26-1470320316689338],[@bibr27-1470320316689338]^ can also be explained by the specific targeting of Ang-(3--4) on Na^+^ transport in renal proximal tubules, in a local tissular environment pathologically modified due to hypertension. Ang-(3--4) strongly inhibits basolateral ouabain-resistant Na^+^-ATPase of SHRs, without any effect on the ouabain-sensitive (Na^+^+K^+^)ATPase or the ouabain-resistant Na^+^-ATPase of healthy rats.^[@bibr33-1470320316689338]^ Orally administrated, it promotes a hypertonic natriuresis only in SHRs. Again, and probably as an indicator of the common mechanism exerted in the basolateral membranes: (a) the physiological effects of Ang-(3−4) requires dissociation of AT~1~R/AT~2~R heterodimers in normal rats ([Figure 6(a)](#fig6-1470320316689338){ref-type="fig"}); and [(b)](#fig6-1470320316689338){ref-type="fig"} inhibition of SHR Na^+^-ATPase is due to AT~2~R upregulating PKA ([Figure 6(b)](#fig6-1470320316689338){ref-type="fig"}).^[@bibr33-1470320316689338]^ The idea of a common cell signaling mechanism receives further support because the counteracting effects of Ang-(3−4) are exerted against AT~1~R-mediated protein kinase C (PKC), one of the most important Ang II-stimulated modulators of transepithelial Na^+^ fluxes in the kidney.^[@bibr10-1470320316689338],[@bibr37-1470320316689338],[@bibr38-1470320316689338],[@bibr42-1470320316689338],[@bibr43-1470320316689338]^ Although the actions of Ang-(3−4) in renal ion-transporting ATPases are significant when intrarenal Ang II levels are high, we should note the hierarchy in these effects: at very low (femtomolar) concentrations range, Ang-(3−4) reactivates the basolateral plasma membrane Ca^2+^-ATPase ([Figure 5(a)](#fig5-1470320316689338){ref-type="fig"}), whereas nanomolar concentrations can inhibit Ang II-stimulated Na^+^-ATPase.^[@bibr33-1470320316689338]^ The resulting effect, requiring a continuous increase in Ang-(3−4) levels (formed from Ang II; [Figure 4](#fig4-1470320316689338){ref-type="fig"}), would first lead *in vivo* to depressed intracellular Ca^2+^, diminished Ca^2+^-dependent PKC activity, recovery of lower basal Na^+^-pumping activity, and depressed active Na^+^ flux towards the peritubular space. Further inhibition of the Na^+^ pump itself -- also by downregulating PKC activity and upregulating PKA^[@bibr41-1470320316689338]−[@bibr43-1470320316689338]^ will occur as Ang-(3−4) increases in concentration.

![(a) Angiotensin-(3−4) (Ang-(3--4)) induces dissociation of Ang II-type 1 receptor (AT~1~R)/Ang II-type 2 receptor(AT~2~R) heterodimers in normotensive rats, but not in spontaneously hypertensive rats (SHRs). SHRs have a constitutively lower content of heterodimers. Immunoprecipitation assays were carried out using specific AT~1~R antibody, followed by western blotting using specific AT~2~R antibody. The specificity of the antibodies was confirmed by preadsorption of the antibodies onto the recombinant immunogenic peptide.^[@bibr48-1470320316689338]^ (b) Inhibition of SHR hyperactive Na^+^ pump by Ang-(3--4) is mediated by protein kinase A (PKA), downstream AT~2~R activation. Na^+^-ATPase activity was assayed without any peptide, or in 10^-8^ mol/L Ang-(3--4) and 10^-6^ mol/L PKA inhibitor peptide PKA~(5-24)~ in the combinations shown on the abscissae. Reproduced from Dias et al.,^[@bibr33-1470320316689338]^ with permission.](10.1177_1470320316689338-fig6){#fig6-1470320316689338}

Even though interaction with AT~2~R seems to play a pivotal role in Ang-(3−4) actions in renal tissue, little is known about its effects and related signaling mechanisms in other organs and tissues. As AT~2~Rs are associated with a myriad of physiological actions in many different organs, and seem to be a common target of small peptides derived from natural proteins,^[@bibr44-1470320316689338]^ Ang-(3−4) actions might have much broader targets than initially thought. Thus it can be speculated that the AT~2~R-mediated effects of Ang-(3−4) might include -- beyond blood pressure control, natriuresis and vasorelaxation -- neural and gastrointestinal actions, as demonstrated for other small peptides that bind to AT~2~R.^[@bibr44-1470320316689338][@bibr45-1470320316689338][@bibr46-1470320316689338]--[@bibr47-1470320316689338]^ Furthermore, AT~2~R-independent mechanisms might also mediate Ang-(3−4) actions in other tissues. The antiproliferative actions of this dipeptide in rat aorta were demonstrated to be independent of angiotensin receptors, but influenced by Ca^2+^-mediated pathways.^[@bibr28-1470320316689338]^ As the Ang-(3−4) influence on Ca^2+^ homeostasis seems to be a critical event in kidney cells,^[@bibr21-1470320316689338],[@bibr40-1470320316689338],[@bibr41-1470320316689338]^ Ca^2+^ would be a signaling intermediate of the dipeptide actions in different tissues.

Conclusion {#section4-1470320316689338}
==========

In summary, Ang-(3--4) can be considered one of the most potent counter-regulators of systemic and local RAS, with an important impact on body-fluid homeostasis through common mechanisms that target renal active transporters of Ca^2+^ and Na^+^, showing natriuretic and antihypertensive effects. As Ang-(3--4) permeates intestinal cells^[@bibr34-1470320316689338]^ and is effective when given orally,^[@bibr26-1470320316689338],[@bibr32-1470320316689338],[@bibr33-1470320316689338]^ it is a potential antagonist of local and systemic Ang II effects for therapeutic purposes.

The excellent technical assistance of Glória Costa-Sarmento is acknowledged. The authors are grateful to Dr Adriana K Carmona and Antonio Miranda (Federal University of São Paulo), Dr Claudio Costa-Neto (University of São Paulo) and Fernanda M Ferrão (State University of Rio de Janeiro) for helpful discussions and experimental collaboration. Correction of the English by BioMedES (UK) is gratefully acknowledged.

**Declaration of conflicting interests:** The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding:** The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research in our laboratories receives financial support from the Brazilian National Research Council/CNPq, the Rio de Janeiro Research State Foundation/Faperj, the Ministry of Health (Department of Science and Technology), the Brazilian Federal Agency for Support and Evaluation of Graduate Education/CAPES, and the Brazilian National Institutes of Science and Technology.
